Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario

Date

21 Oct 2023

Session

Poster session 09

Topics

Tumour Immunology;  Immunotherapy

Tumour Site

Central Nervous System Malignancies

Presenters

Santiago Cabezas-Camarero

Citation

Annals of Oncology (2023) 34 (suppl_2): S391-S409. 10.1016/S0923-7534(23)01934-8

Authors

S. Cabezas-Camarero1, R. Pérez-Alfayate2, M.J. Sotelo Lezama3, P. Pérez Segura4

Author affiliations

  • 1 Medical Oncology Department, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 2 Neurosurgery, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 3 Medical Oncology Department, Hospital Maria Auxiliadora, 15046 - Lima/PE
  • 4 Dept. Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 511P

Background

Disruption of the immune system is known to favor carcinogenesis and cancer breakthrough. Gliomas constitute de most prevalent primary malignant brain tumors. We aimed to study the occurrence of immune disruptive conditions (IDC) in patients with gliomas at our institution.

Methods

Retrospective study of patients (pts) diagnosed with a glioma at Hospital Clínico Universitario San Carlos, Madrid (Spain). IDCs included autoimmune diseases (AID), organ transplantation (OT) requiring chronic immunosuppressive therapy (IST), and hematological malignancies (HM). A descriptive study, as well as time since IDC, time under IST, and progression-free survival (PFS) and overall survival (OS) since glioma diagnosis were analyzed.

Results

Within the period January 1999 – April 2023, among 481 patients diagnosed with a glioma, 30 (6.2%) patients harbored IDCs. Male/Female: 14/16. Age: 63y (32-83). WHO 5th Ed.: IDH-WT GB: n=26 (MGMTmeth: 50%, MGMTunmeth: 50%), IDH-MUT Astro: n=3, Pleomorphic xanthoastro: n=1. Frontal: n=14, Temporal: n=8, Parietal: n=6. Unilobar: n=23, Bilobar: n=4, Trilobar: n=1. Right: n=8, Left: n=19, Bilateral: n=3. Resection: GTR=8, STR=1, Partial=3, Biopsy=14. RTx=20 pts, CRTx=18, Adj CTx=13. Median PFS and OS since diax were 9 and 10 months (m), respectively. No. of IDCs: 1 (n=21 pts), ≥ 2 (n=9 pts). IDC type: AID (n=27 pts) among which: endocrine (4: Addison, Hypothyroidism, Hashimoto's thyroiditis), respiratory (7: asthma, sarcoidosis, alergic rinoconjunctivitis), cutaneous (7: chronic eccema, psoriasis), neurological (4: multiple sclerosis, Guillain-Barré), digestive system (2: inflammatory bowel disease), rheumatological (13: Horton's disease, Sjöegren's syndrome, systemic lupus erithematosus, uveitis, vasculitis); HM (1: chronic lymphocytic leukaemia); OT (2: renal). IST for IDCs used in 20 pts (systemic IST in 17). Median time since IDC: 101 m (10-411). Median time under IST: 108 m (0-283).

Conclusions

Within a large 24-year long retrospective series, a minority of pts with glioma harbored an IDC, most commonly rheumatological, respiratory, or cutaneous. Studies should be conducted to unveil if gliomas occurring in pts with IDCs are biologically and immunologically distinct.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. Cabezas-Camarero: Financial Interests, Personal, Invited Speaker: MSD, Bristol Myers Squibb, Janssen; Non-Financial Interests, Personal, Funding, Research project Head and Neck Cancer: Merck KgGa; Other, Personal, Other, Travel arrangement: Merck KgGa; Other, Personal, Other, Travel arrangements: Janssen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.